Elsevier

Journal of Hepatology

Volume 69, Issue 2, August 2018, Pages 275-277
Journal of Hepatology

Editorial
Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis

https://doi.org/10.1016/j.jhep.2018.05.012Get rights and content

Section snippets

Financial support

Grant support received: U01 AA021788 – Treat Mayo (Shah – PI).

Conflict of interest

VS reports personal fees from Novartis Pharmaceuticals, Durect Corporation, Merck Research Laboratories, Afimmune Ltd., outside the submitted work. The other authors have no conflicts of interest.

Please refer to the accompanying ICMJE disclosure forms for further details.

References (20)

There are more references available in the full text version of this article.

Cited by (12)

  • Antarctic krill oil ameliorates liver injury in rats exposed to alcohol by regulating bile acids metabolism and gut microbiota

    2022, Journal of Nutritional Biochemistry
    Citation Excerpt :

    On the other hand, the activation of intestinal FXR can induce intestine cells to secrete FGF15 [53]. FGF15 is an endocrine gastrointestinal hormone that binds FGFR4 in the liver, suppresses the hepatocyte expression of CYP7A1, and inhibits BAs synthesis, thereby creating a negative feedback loop [54]. The decreased activity of FXR in enterocytes of the terminal ileum caused by alcohol intake resulted in less FGF15 protein in the ileum and increased hepatic CYP7A1 protein expression, which likely contributed to increased total plasma and hepatic BAs after chronic ethanol feeding [9].

  • Emerging Therapies for Alcoholic Hepatitis

    2021, Clinics in Liver Disease
    Citation Excerpt :

    They bind to bile acid, producing fibroblast growth factor 19, which plays a role in negative feedback controlling of bile acid synthesis, decreasing fatty acid synthesis, and promoting fatty acid oxidation in the liver. Moreover, FXR agonist showed anti-inflammatory activity, antioxidant activity, and hepatic hemodynamic benefits, with an improvement in portal hypertension in animal studies.55–57 Obeticholic acid (OCA) is an FXR agonist and a semisynthetic derivative of the chenodeoxycholic acid; it was studied in patients with primary biliary cholangitis and nonalcoholic steatohepatitis (NASH), showing promising efficacy.58,59

  • Acute Alcoholic Hepatitis

    2019, Clinics in Liver Disease
    Citation Excerpt :

    The FXR agonist obeticholic acid, approved for primary biliary cholangitis, was recently issued a boxed warning by the US Food and Drug Administration for deaths linked to inappropriate dosing in patients with hepatic impairment (Child class B or C or patients with prior hepatic decompensation). Although even patients with moderate AH may meet these criteria, a highly anticipated phase II trial in moderate AH is currently on hold.58 Abstinence from alcohol is the cornerstone of AH treatment.

  • The Mexican consensus on alcoholic hepatitis

    2020, Revista de Gastroenterologia de Mexico
View all citing articles on Scopus

Guest Editor: Didier Samuel.

View full text